Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899155 · ClinicalTrials.gov registry record · Phase 2
Pan Tumor Rollover Study
A Phase 2 study of Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,500
- Enrollment target
- 20
- Study locations
NCT03899155 is a Phase 2 study of Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,500 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03899155, a Phase 2 study of Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Relatlimab
- DRUG Cabozantinib
- DRUG Trametinib
Study Locations (20)
California
- Innovative Clinical Research Institute - Lynwood
- Local Institution - San Francisco
- Local Institution - 0099 - San Francisco
Florida
- Florida Cancer Affiliates - Ocala
- Local Institution - Orlando
- Local Institution - 0024 - Tampa
Illinois
- Local Institution - 0105 - Chicago
- Local Institution - Maywood
- Local Institution - 0279 - Park Ridge
Kansas
- Local Institution - 0186 - Westwood
- Local Institution - 0165 - Wichita
Massachusetts
- Local Institution - 0039 - Boston
- Dana_Farber Cancer Institute (DFCI) - Boston
Alabama
- Local Institution - 0220 - Huntsville
Arizona
- University of Arizona College of Medicine - Tucson
Colorado
- Local Institution - 0233 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2029-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03899155
The ClinicalTrials.gov registry entry for NCT03899155 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (57% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT03899155 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03899155 about?
NCT03899155 is a clinical study titled "Pan Tumor Rollover Study". Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
What is the current status of trial NCT03899155?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,500 participants. The study started on 2020-05-05. Estimated completion is 2029-08-25.
What conditions does trial NCT03899155 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03899155?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Relatlimab (DRUG), Cabozantinib (DRUG), Trametinib (DRUG).
Who is sponsoring clinical trial NCT03899155?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899155 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.